Actinium Pharmaceuticals, Inc.

AMEX:ATNM

Biotechnology

Healthcare
$1.64 +15.94%

+$0.22 today

Market cap
$51.56M
Beta
0.02
P/E (TTM)
4.4
EPS (TTM)
$0.36
52W Low $0.74High $1.74

Volume 0.18M

Average 0.15M

Cash Flow

Check whether earnings turn into cash.

Operating Cash Flow

-$24.58M

FY 2025 · Annual

Investing Cash Flow

-$104,000.00

FY 2025 · Annual

Financing Cash Flow

-$217,000.00

FY 2025 · Annual

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(24.77M)(33.02M)(48.82M)(38.24M)(33.89M)
Depreciation & Amortization524K699K790K811K821K
Deferred Income Tax(1.55M)402K000
Stock-Based Compensation1.69M2.8M3.84M5.29M9.19M
Change in Working Capital1.69M38.17M(3.15M)(932K)(704K)
Accounts Receivables00000
Inventory00000
Accounts Payables1.2M4.6M(2.18M)(387K)(346K)
Other Working Capital495K33.57M(972K)(545K)(358K)
Other Non-Cash Items1.55M(402K)000
Operating Cash Flow(20.87M)8.64M(47.34M)(33.07M)(24.58M)
Capital Expenditures(133K)(366K)(153K)(11K)(104K)
Acquisitions (Net)00000
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities00000
Investing Cash Flow(133K)(366K)(153K)(11K)(104K)
Debt Repayment(85K)(49K)(4K)(9K)(10K)
Common Stock Issued35.3M23.16M14.87M29.26M0
Common Stock Repurchased0000(207K)
Dividends Paid00000
Other Financing Activities6K0075K0
Financing Cash Flow35.22M23.11M14.87M29.32M(217K)
Effect of Forex Changes00(11K)06K
Net Change in Cash14.22M31.39M(32.63M)(3.76M)(24.9M)
Free Cash Flow(21M)8.28M(47.49M)(33.08M)(24.68M)

Free Cash Flow

Net Income to FCF bridge

FY2025

= Net Income-$33.9M
+ D&A$821.0K
+ Stock-Based Comp$9.2M
+ Deferred Tax$0
- Working Capital-$704.0K
+ Other Non-Cash$0
= Operating Cash Flow-$24.6M
- Capex-$104.0K
= Free Cash Flow-$24.7M

Analysis

FY2025 free cash flow is -$24.7M. FCF conversion is 72.8% of net income. Operating cash flow was -$24.6M, with capex of -$104.0K. The largest bridge item is Stock-Based Comp at $9.2M.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
4Statement of changes in beneficial ownershipOct 16, 2026
3Initial statement of beneficial ownershipOct 16, 2026
8-KCurrent reportOct 15, 2026
DEF 14ADEF 14A filingOct 15, 2026
ARSARS filingOct 15, 2026

Does ATNM generate free cash flow?

Actinium Pharmaceuticals, Inc. (ATNM) generated -$24.68M of free cash flow in fiscal 2025.

How much operating cash flow does ATNM produce?

Operating cash flow was -$24.58M, before capital expenditures of $104,000.00.